A week post Bayer’s announcement on the withdrawal of Essure, its contraceptive implant from the market by this year-end due to inadequate sales, its clinical safety is questioned as consumer and legal stress builds up concerning complaints of extreme fatigue, pain and bleeding.
Bayer announced on last Friday that it would stop the sales of its Essure birth control system in the United States by the end of this year due to a steady decline in its sales making the product no longer justifiable. Bayer insisted that its decision to discontinue Essure sales is only for business reasons and not for any safety or efficacy concerns.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.